Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
DOI:
https://doi.org/10.2340/00015555-3816Keywords:
interleukin-17A, psoriasis, PASI 90, secukinumabAbstract
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.
Downloads
References
Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of psoriasis and psoriatic arthritis in Italy - a systematic review. Curr Rheumatol Rep 2018; 20: 43.
https://doi.org/10.1007/s11926-018-0753-1 DOI: https://doi.org/10.1007/s11926-018-0753-1
Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-1204.
https://doi.org/10.1016/S0140-6736(03)12954-6 DOI: https://doi.org/10.1016/S0140-6736(03)12954-6
Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care 2016; 22: s216-224.
Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-275.
https://doi.org/10.1067/S0190-9622(03)01479-8 DOI: https://doi.org/10.1067/S0190-9622(03)01479-8
Radtke MA, Langenbruch AK, Schafer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6.
https://doi.org/10.2147/PROM.S14861 DOI: https://doi.org/10.2147/PROM.S14861
Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 2014; 71: 141-150.
https://doi.org/10.1016/j.jaad.2013.12.036 DOI: https://doi.org/10.1016/j.jaad.2013.12.036
Bagel J. Treat to target in psoriasis: A real-world experience with biologics and adjunctive topical therapy. J Drugs Dermatol 2018; 17: 918.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
https://doi.org/10.1038/jid.2012.339 DOI: https://doi.org/10.1038/jid.2012.339
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534-2548.
https://doi.org/10.1056/NEJMoa1505066 DOI: https://doi.org/10.1056/NEJMoa1505066
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
https://doi.org/10.1056/NEJMoa1314258 DOI: https://doi.org/10.1056/NEJMoa1314258
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1137-1146.
https://doi.org/10.1016/S0140-6736(15)61134-5 DOI: https://doi.org/10.1016/S0140-6736(15)61134-5
Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 400-409.
https://doi.org/10.1016/j.jaad.2015.05.013 DOI: https://doi.org/10.1016/j.jaad.2015.05.013
Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. J Clin Aesthet Dermatol 2016; 9: S3-S6.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76: 60-69.
https://doi.org/10.1016/j.jaad.2016.08.008 DOI: https://doi.org/10.1016/j.jaad.2016.08.008
Bissonnette R, Luger T, Thaci D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.
https://doi.org/10.1111/jdv.14878 DOI: https://doi.org/10.1111/jdv.14878
Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. J Dermatolog Treat 2014; 25: 78-82.
https://doi.org/10.3109/09546634.2013.826341 DOI: https://doi.org/10.3109/09546634.2013.826341
Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-251.
https://doi.org/10.1016/j.jaad.2010.12.005 DOI: https://doi.org/10.1016/j.jaad.2010.12.005
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
https://doi.org/10.1016/S0140-6736(05)67566-6 DOI: https://doi.org/10.1016/S0140-6736(05)67566-6
Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
https://doi.org/10.1001/archderm.143.6.719 DOI: https://doi.org/10.1001/archderm.143.6.719
Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, et al. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. Br J Dermatol 2017; 177: 411-418.
https://doi.org/10.1111/bjd.15381 DOI: https://doi.org/10.1111/bjd.15381
Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, et al. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol 2020; 182: 67-75.
https://doi.org/10.1111/bjd.17991 DOI: https://doi.org/10.1111/bjd.17991
Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol 2018; 179: 1072-1080.
https://doi.org/10.1111/bjd.16705 DOI: https://doi.org/10.1111/bjd.16705
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: results from extension phase of the SUPREME study. Br J Dermatol 2019; 181: 413-414.
https://doi.org/10.1111/bjd.18013 DOI: https://doi.org/10.1111/bjd.18013
Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003; 14: 158-165.
https://doi.org/10.1080/09546630310013360 DOI: https://doi.org/10.1080/09546630310013360
Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015; 26: 23-31.
https://doi.org/10.3109/09546634.2013.865009 DOI: https://doi.org/10.3109/09546634.2013.865009
Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 2015; 29: 645-648.
https://doi.org/10.1111/jdv.12817 DOI: https://doi.org/10.1111/jdv.12817
Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat 2018; 29: 334-346.
https://doi.org/10.1080/09546634.2017.1395794 DOI: https://doi.org/10.1080/09546634.2017.1395794
Committee for medicinal products for human use. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. 2004 [cited 2021 March 11]; Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-indicated-treatment-psoriasis_en.pdf.
Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014; 70: 146-167.
https://doi.org/10.1016/j.jaad.2013.08.042 DOI: https://doi.org/10.1016/j.jaad.2013.08.042
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat 2020; 31: 476-483.
https://doi.org/10.1080/09546634.2019.1671577 DOI: https://doi.org/10.1080/09546634.2019.1671577
Georgakopoulos JR, Ighani A, Phung M, Yeung J. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol 2018; 78: 1019-1020.
https://doi.org/10.1016/j.jaad.2017.11.036 DOI: https://doi.org/10.1016/j.jaad.2017.11.036
Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol 2020; 34: 1161-1173.
https://doi.org/10.1111/jdv.16124 DOI: https://doi.org/10.1111/jdv.16124
Galluzzo M, Talamonti M, De Simone C, D'Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018; 18: 727-735.
https://doi.org/10.1080/14712598.2018.1481503 DOI: https://doi.org/10.1080/14712598.2018.1481503
Georgakopoulos JR, Ighani A, Zhou LL, Yeung J. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol 2018; 32: e32-e34.
https://doi.org/10.1111/jdv.14468 DOI: https://doi.org/10.1111/jdv.14468
Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One 2018; 13: e0195123.
https://doi.org/10.1371/journal.pone.0195123 DOI: https://doi.org/10.1371/journal.pone.0195123
Yanaba K, Umezawa Y, Ito T, Hayashi M, Kikuchi S, Fukuchi O, et al. Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. Arch Dermatol Res 2014; 306: 921-925.
https://doi.org/10.1007/s00403-014-1495-1 DOI: https://doi.org/10.1007/s00403-014-1495-1
Waist circumference and waist-hip ratio: report of a WHO expert consultation: WHO Press; 2008: p. 12-13. Available from: https://apps.who.int/iris/bitstream/handle/10665/44583/9789241501491_eng.pdf;jsessionid=1F265172A24E24AF4E26920E4F8EE12A?sequence=1.
Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' health study II. Arch Intern Med 2007; 167: 1670-1675.
https://doi.org/10.1001/archinte.167.15.1670 DOI: https://doi.org/10.1001/archinte.167.15.1670
Kumar S, Han J, Li T, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27: 1293-1298.
https://doi.org/10.1111/jdv.12001 DOI: https://doi.org/10.1111/jdv.12001
Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 2014; 13: 981-1000.
https://doi.org/10.1016/j.autrev.2014.07.001 DOI: https://doi.org/10.1016/j.autrev.2014.07.001
Toussirot E, Aubin F, Dumoulin G. Relationships between adipose tissue and psoriasis, with or without arthritis. Front Immunol 2014; 5: 368.
https://doi.org/10.3389/fimmu.2014.00368 DOI: https://doi.org/10.3389/fimmu.2014.00368
Published
How to Cite
License
Copyright (c) 2021 Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
